QT-019C

Developed for: idiopathic inflammatory myopathy · systemic lupus erythematosus · anti-neutrophil cytoplasmic antibody-associated vasculitis · autoimmune thrombocytopenia · autoimmune thrombocytopenic purpura · multiple sclerosis · myasthenia gravis · neuromyelitis optica
+1 more
· systemic sclerosis
Investigated by: Shanghai Xiniao Biotech Co., Ltd. · Institute of Hematology & Blood Diseases Hospital, China · The Affiliated Hospital of Xuzhou Medical University · Tianjin Huanhu Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

2026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT07392528	Mar 2026 → Jun 2027 expected	multiple sclerosis, myasthenia gravis, neuromyelitis optica	Tianjin Huanhu Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT07410377	Mar 2026 → Mar 2027	idiopathic inflammatory myopathy, systemic lupus erythematosus	The Affiliated Hospital of Xuzhou Medical University	Withdrawn	No outcome recorded
Phase 0	NCT07416032	Feb 2026 → Jun 2028 expected	autoimmune thrombocytopenia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Not yet recruiting	No outcome recorded
Phase 11 trial
Phase 1	NCT07315087	Jan 2026 → Jan 2029 expected	anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune thrombocytopenic purpura, idiopathic inflammatory myopathy, systemic lupus erythematosus +1	Institute of Hematology & Blood Diseases Hospital, China	Recruiting	No outcome recorded

Date	Issuer	Release
2026-05-15	Hangzhou Qihan Biotech Co., Ltd.	Regulatory Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases qihanbio.com ↗

Date	Issuer	Release
2026-05-15	Hangzhou Qihan Biotech Co., Ltd.	Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases qihanbio.com ↗

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	QT-019C	“QT-019C will be administered intravenously as per the schedule specified in the protocol.” NCT07410377 ↗ 3 NCT07392528 ↗ NCT07315087 ↗ NCT07416032 ↗
Modality	Cell therapy	“CAR T-cell Therapy” NCT07315087 ↗
Route	Intravenous	“administered intravenously” NCT07315087 ↗
Target	CD19	“universal allogeneic anti-CD19/BCMA CAR T-cells” NCT07315087 ↗